Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
- 31 May 2005
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 95 (1-5) , 91-95
- https://doi.org/10.1016/j.jsbmb.2005.04.017
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast CancerAnnals of Surgical Oncology, 2001
- Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsiesThe Pharmacogenomics Journal, 2001
- Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?JNCI Journal of the National Cancer Institute, 2000